In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A "Wish List" Comes True at Matrix

Executive Summary

The FDA has been getting tougher on cancer drugs. Lately, it's been asking drugmakers to provide proof not just that their therapies can shrink tumors, but that doing so actually benefits patients--in a way that matters to those patients, not just their doctors. Matrix Pharmaceutical Inc. thinks it got that proof, by asking patients and physicians to choose, before they began participating in its clinical studies, the clinical endpoints they would most like to realize from treatment with IntraDose, a gel-based formulation of the well-known chemotherapeutic agent cisplatin.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts